A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Halda Therapeutics OpCo, Inc.
Immuneering Corporation
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Immuneering Corporation
Imugene Limited
Opna Bio LLC
Nimbus Therapeutics
Mural Oncology, Inc
ZielBio, Inc.
Aravive, Inc.
QureBio Ltd.
Tracon Pharmaceuticals Inc.
Lumos Pharma
Acrotech Biopharma Inc.
Celldex Therapeutics
Silence Therapeutics GmbH
Axcentua Pharmaceuticals AB
ARCA Biopharma, Inc.